Fighting Freddie returns home from pioneering treatment in Germany

FIGHTING Freddie Rowe-Crowder has completed the first round of pioneering antibody treatment in Germany.

Eight-year-old Freddie, a pupil at St Helen’s School, was diagnosed with neuroblastoma in February last year and, although doctors initially told Freddie’s parents Tep Crowder and Tania Rowe that his condition was terminal, he fought back against all the odds and it is hoped that the latest set of treatment will give him a shot at survival.

Freddie, whose �60,000 medication was partly made possible by a Herts Advertiser fundraising campaign, spent 16 days undergoing relentless treatment in Germany and Tep said that it has had some peculiar side effects: “The treatment gave Freddie a fever and the constant morphine made him itch.

“Overall, though, he’s doing fantastically. The doctors are amazed at the way he copes with the treatment and the good grace and bravery with which he approaches it.”

Freddie, who according to Tep replies that he is “brilliant” when asked, landed in England on Tuesday night, but because doctors decided in June to also give him immunotherapy treatment between cycles, Tep said that Freddie has not yet had time to rest.


You may also want to watch:


He added: “Freddie’s made lots of friends on the oncology ward and, though they can’t understand each other, they have the common language of Nintendo!”

The Rowe-Crowder family will return to Germany at the beginning of next month, when Freddie will undergo tests to see how successful the treatment has been. Tep said that after that, the family can look forward to a long weekend away in a cottage, courtesy of children’s cancer charity Adam’s Hats.

Most Read

Become a Supporter

This newspaper has been a central part of community life for many years. Our industry faces testing times, which is why we're asking for your support. Every contribution will help us continue to produce local journalism that makes a measurable difference to our community.

Become a Supporter
Comments powered by Disqus